Gastrointestinal Bleeding in Congenital Bleeding Disorders

Abstract

Gastrointestinal bleeding (GIB) is serious, intractable, and potentially life-threatening condition. There is considerable heterogeneity in GIB phenotypes among congenital bleeding disorders (CBDs), making GIB difficult to manage. Although GIB is rarely encountered in CBDs, its severity in some patients makes the need for a comprehensive and precise assessment of underlying factors and management approaches imperative. Initial evaluation of GIB begins with assessment of hematological status; GIB should be ruled out in patients with chronic anemia, and in presentations that include hematemesis, hematochezia, or melena. High-risk patients with recurrent GIB require urgent interventions such as replacement therapy for treatment of coagulation factor deficiency (CFD). However, the best management strategy for CFD-related bleeding remains controversial. While several investigations have identified CBDs as potential risk factors for GIB, research has focused on assessing the risks for individual factor deficiencies and other CBDs. This review highlights recent findings on the prevalence, management strategies, and alternative therapies of GIB related to CFDs, and platelet disorders.

Keywords

gastrointestinal bleeding - congenital bleeding disorders - hemorrhage - replacement therapy - coagulation factors deficiency

Publikationsverlauf

Artikel online veröffentlicht:
12. Januar 2022

• References

• 1 Makris M, Federici AB, Mannucci PM. et al. The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease. Haemophilia 2015; 21 (03) 338-342
• 2 Tsagianni A, Comer DM, Yabes JG, Ragni MV. Von Willebrand disease and gastrointestinal bleeding: a national inpatient sample study. Thromb Res 2019; 178: 119-123
• 3 Sigounas DE, Yung DE, Plevris JN, Koulaouzidis A. Angioectasias on the major and accessory duodenal papillae; a unique cause of recurrent bleed in a patient with von Willebrand's disease. BMJ Case Rep 2015; 2015: 142-157
• 4 Castaman G, Federici AB, Tosetto A. et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost 2012; 10 (04) 632-638
• 5 Franchini M, Mannucci PM. Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. Thromb Haemost 2014; 112 (03) 427-431
• 6 Acharya SS, Coughlin A, Dimichele DM. North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2 (02) 248-256
• 7 de Wee EM, Sanders YV, Mauser-Bunschoten EP. et al; WiN study group. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost 2012; 108 (04) 683-692
• 8 Ramsay DM, Buist TA, Macleod DA, Heading RC. Persistent gastrointestinal bleeding due to angiodysplasia of the gut in von Willebrand's disease. Lancet 1976; 2 (7980): 275-278
• 9 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
• 10 Pavlova A, Oldenburg J. Defining severity of hemophilia: more than factor levels. Semin Thromb Hemost 2013; 39 (07) 702-710
• 11 Mittal R, Spero JA, Lewis JH. et al. Patterns of gastrointestinal hemorrhage in hemophilia. Gastroenterology 1985; 88 (02) 515-522
• 12 Forbes CD, Barr RD, Prentice CR, Douglas AS. Gastrointestinal bleeding in haemophilia. Q J Med 1973; 42 (167) 503-511
• 13 Dorgalaleh A, Alavi SE, Tabibian S. et al. Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran. Hematology 2017; 22 (04) 224-230
• 14 Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351 (07) 683-694
• 15 Rao AK. Inherited platelet function disorders: overview and disorders of granules, secretion, and signal transduction. Hematol Oncol Clin North Am 2013; 27 (03) 585-611
• 16 Brown DL. Congenital bleeding disorders. Curr Probl Pediatr Adolesc Health Care 2005; 35 (02) 38-62
• 17 Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knöbl P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost 2010; 104 (03) 563-570
• 18 Wang L, Rosenberg JB, De BP. et al. In vivo gene transfer strategies to achieve partial correction of von Willebrand disease. Hum Gene Ther 2012; 23 (06) 576-588
• 19 Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood 2015; 125 (13) 2029-2037
• 20 James PD, Goodeve AC. von Willebrand disease. Genet Med 2011; 13 (05) 365-376
• 21 Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Hematology (Am Soc Hematol Educ Program) 2013; 2013: 254-260
• 22 James PD, Notley C, Hegadorn C. et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109 (01) 145-154
• 23 Nichols WL, Hultin MB, James AH. et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (02) 171-232
• 24 Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24 (03) 123-134
• 25 Castaman G, Tosetto A, Eikenboom JC, Rodeghiero F. Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza. J Thromb Haemost 2010; 8 (09) 2078-2080
• 26 Rydz N, Swystun LL, Notley C. et al. The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood 2013; 121 (26) 5228-5237
• 27 Rastegarlari G, Pegon JN, Casari C. et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood 2012; 119 (09) 2126-2134
• 28 Veyradier A, Balian A, Wolf M. et al. Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract. Gastroenterology 2001; 120 (02) 346-353
• 29 Morris ES, Hampton KK, Nesbitt IM, Preston FE, Thomas EG, Makris M. The management of von Willebrand's disease-associated gastrointestinal angiodysplasia. Blood Coagul Fibrinolysis 2001; 12 (02) 143-148
• 30 Satoh Y, Kita H, Kihira K. et al. Gastrointestinal angiodysplasia in a patient with type 2 von Willebrand's disease and analysis of exon 28 of the von Willebrand factor gene. Am J Gastroenterol 2004; 99 (12) 2495-2498
• 31 Sadler JE, Budde U, Eikenboom JC. et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
• 32 Tosetto A, Badiee Z, Baghaipour MR. et al. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: results from 3WINTERS-IPS, an international and collaborative cross-sectional study. J Thromb Haemost 2020; 18 (09) 2145-2154
• 33 Holm E, Carlsson KS, Lövdahl S, Lail AE, Abshire TC, Berntorp E. Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network. Haemophilia 2018; 24 (04) 628-633
• 34 Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E. Evolution of replacement therapy for von Willebrand disease: from plasma fraction to recombinant von Willebrand factor. Blood Rev 2019; 38: 100572
• 35 Berntorp E, Windyga J. European Wilate Study Group. Treatment and prevention of acute bleedings in von Willebrand disease–efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia 2009; 15 (01) 122-130
• 36 Makris M. Gastrointestinal bleeding in von Willebrand disease. Thromb Res 2006; 118 (Suppl. 01) S13-S17
• 37 Heijdra JM, Cnossen MH, Leebeek FWG. Current and emerging options for the management of inherited von Willebrand disease. Drugs 2017; 77 (14) 1531-1547
• 38 Brown R. Recombinant von Willebrand factor for severe gastrointestinal bleeding unresponsive to other treatments in a patient with type 2A von Willebrand disease: a case report. Blood Coagul Fibrinolysis 2017; 28 (07) 570-575
• 39 Leebeek FWG, Atiq F. How I manage severe von Willebrand disease. Br J Haematol 2019; 187 (04) 418-430
• 40 Coppola A, Franchini M, Makris M, Santagostino E, Di Minno G, Mannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia 2012; 18 (03) e173-e187
• 41 Federici AB, Gianniello F, Canciani MT, Mannucci PM. Secondary long-term prophylaxis in severe patients with von Willebrand's disease: an Italian cohort study. Blood 2005; 106 (11) 1782-1782
• 42 Federici AB, Castaman G, Franchini M. et al. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica 2007; 92 (07) 944-951
• 43 Coppola A, Cimino E, Conca P. et al. Long-term prophylaxis with intermediate-purity factor VIII concentrate (Haemate P) in a patient with type 3 von Willebrand disease and recurrent gastrointestinal bleeding. Haemophilia 2006; 12 (01) 90-94
• 44 Abshire TC, Federici AB, Alvárez MT. et al; VWD PN. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2013; 19 (01) 76-81
• 45 Eugster M, Reinhart WH. The influence of the haematocrit on primary haemostasis in vitro. Thromb Haemost 2005; 94 (06) 1213-1218
• 46 Meijer K, Peters FT, van der Meer J. Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. Blood Coagul Fibrinolysis 2001; 12 (03) 211-213
• 47 Nomikou E, Tsevrenis V, Gafou A, Bellia M, Theodossiades G. Type IIb von Willebrand disease with angiodysplasias and refractory gastrointestinal bleeding successfully treated with thalidomide. Haemophilia 2009; 15 (06) 1340-1342
• 48 Bowers M, McNulty O, Mayne E. Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia in two patients with von Willebrand's disease. Br J Haematol 2000; 108 (03) 524-527
• 49 Khatri NV, Patel B, Kohli DR, Solomon SS, Bull-Henry K, Kessler CM. Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease. Haemophilia 2018; 24 (02) 278-282
• 50 Alikhan R, Keeling D. Von Willebrand disease, angiodysplasia and atorvastatin. Br J Haematol 2010; 149 (01) 159-160
• 51 Sohal M, Laffan M. Von Willebrand disease and angiodysplasia responding to atorvastatin. Br J Haematol 2008; 142 (02) 308-309
• 52 Thachil J, Hay CR, Campbell S. Tamoxifen for recurrent bleeds due to angiodysplasia in von Willebrand's disease. Haemophilia 2013; 19 (05) e313-e315
• 53 Botero JP, Pruthi RK. Refractory bleeding from intestinal angiodysplasias successfully treated with danazol in three patients with von Willebrand disease. Blood Coagul Fibrinolysis 2013; 24 (08) 884-886
• 54 Mannucci PM, Kempton C, Millar C. et al; rVWF Ad Hoc Study Group. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood 2013; 122 (05) 648-657
• 55 Tran T, Arnall J, Moore DC, Ward L, Palkimas S, Man L. Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience. J Thromb Thrombolysis 2020; 49 (03) 431-440
• 56 Leebeek F, Chapman M, Ploder B, Sytkowski A, Novack A, Ewenstein B. Treatment of gastrointestinal bleeding episodes with recombinant von Willebrand factor (rVWF) in patients with severe von Willebrand disease (VWD): sub-analysis from pivotal phase III on-demand study. Res Pract Thromb Haemost 2017; 1 (Suppl. 01) 880-897
• 57 Peyvandi F, Mamaev A, Wang JD. et al. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. J Thromb Haemost 2019; 17 (01) 52-62
• 58 Gill JC, Castaman G, Windyga J. et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood 2015; 126 (17) 2038-2046
• 59 Fijnvandraat K, Cnossen MH, Leebeek FW, Peters M. Diagnosis and management of haemophilia. BMJ 2012; 344: e2707
• 60 O'Hara J, Walsh S, Camp C. et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes 2018; 16 (01) 84-97
• 61 Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16 (01) 20-32
• 62 Soucie JM, Miller CH, Dupervil B, Le B, Buckner TW. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia 2020; 26 (03) 487-493
• 63 Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorb 2011; 1: 51-59
• 64 Mansouritorghabeh H. Clinical and laboratory approaches to hemophilia A. Iran J Med Sci 2015; 40 (03) 194-205
• 65 Pickles CW, Biss T, Bitar R. Gastrointestinal bleeding in children with hemophilia A. Clin Pediatr (Phila) 2018; 57 (07) 854-856
• 66 Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol 2012; 81 (01) 82-93
• 67 Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4 (01) 59-72
• 68 Dorgalaleh A, Dadashizadeh G, Bamedi T. Hemophilia in Iran. Hematology 2016; 21 (05) 300-310
• 69 Mannucci PM. Use of desmopressin in the treatment of hemophilia A: towards a golden jubilee. Haematologica 2018; 103 (03) 379-381
• 70 Szczepanic A. Treatment of upper gastrointestinal bleeding in patients with hemophilia. Pol J Surg 2002; 74: 1003-1016
• 71 Szczepanik AB, Zaleska M, Wiszniewski A. et al. Helicobacter pylori infection in patients with haemophilia in Poland: prevalence and risk of upper gastrointestinal bleeding. Haemophilia 2005; 11 (04) 376-379
• 72 Srivastava A, Brewer AK, Mauser-Bunschoten EP. et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
• 73 Levy JH, Koster A, Quinones QJ, Milling TJ, Key NS. Antifibrinolytic therapy and perioperative considerations. Anesthesiology 2018; 128 (03) 657-670
• 74 Callaghan MU, Sidonio R, Pipe SW. Novel therapeutics for hemophilia and other bleeding disorders. Blood 2018; 132 (01) 23-30
• 75 Rick ME, Walsh CE, Key NS. Congenital bleeding disorders. Hematology (Am Soc Hematol Educ Program) 2003; 559-574
• 76 Manco-Johnson MJ, Abshire TC, Shapiro AD. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (06) 535-544
• 77 Peyvandi F, Cattaneo M, Inbal A, De Moerloose P, Spreafico M. Rare bleeding disorders. Haemophilia 2008; 14 (Suppl. 03) 202-210
• 78 Peyvandi F, Palla R, Menegatti M, Mannucci PM. Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management. Semin Thromb Hemost 2009; 35 (04) 349-355
• 79 Peyvandi F, Garagiola I, Biguzzi E. Advances in the treatment of bleeding disorders. J Thromb Haemost 2016; 14 (11) 2095-2106
• 80 Peyvandi F, Spreafico M. National and international registries of rare bleeding disorders. Blood Transfus 2008; 6 (2, Suppl 2) s45-s48
• 81 Peyvandi F, Palla R, Menegatti M. et al; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10 (04) 615-621
• 82 World Federation of Hemophilia. World Federation of Hemophilia report on the Annual Global Survey 2019. 2020
• 83 Borhany M, Pahore Z, Ul Qadr Z. et al. Bleeding disorders in the tribe: result of consanguineous in breeding. Orphanet J Rare Dis 2010; 5: 23-27
• 84 Jaouad IC, Elalaoui SC, Sbiti A, Elkerh F, Belmahi L, Sefiani A. Consanguineous marriages in Morocco and the consequence for the incidence of autosomal recessive disorders. J Biosoc Sci 2009; 41 (05) 575-581
• 85 Tonbary YA, Elashry R, Zaki MelS. Descriptive epidemiology of hemophilia and other coagulation disorders in Mansoura, Egypt: retrospective analysis. Mediterr J Hematol Infect Dis 2010; 2 (03) e2010025
• 86 Saadat M, Ansari-Lari M, Farhud DD. Consanguineous marriage in Iran. Ann Hum Biol 2004; 31 (02) 263-269
• 87 Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia 2002; 8 (03) 308-321
• 88 Peyvandi F, Menegatti M, Palla R. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. Semin Thromb Hemost 2013; 39 (06) 579-584
• 89 Peyvandi F, Kunicki T, Lillicrap D. Genetic sequence analysis of inherited bleeding diseases. Blood 2013; 122 (20) 3423-3431
• 90 Brenner B, Kuperman AA, Watzka M, Oldenburg J. Vitamin K-dependent coagulation factors deficiency. Semin Thromb Hemost 2009; 35 (04) 439-446
• 91 Napolitano M, Mariani G, Lapecorella M. Hereditary combined deficiency of the vitamin K-dependent clotting factors. Orphanet J Rare Dis 2010; 5: 21-35
• 92 Dorgalaleh A, Tabibian S, Hosseini MS, Shams M. Pharmacological management of rare coagulation factor deficiencies besides hemophilia. Expert Rev Hematol 2020; 13 (08) 811-834
• 93 Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost 2009; 7 (Suppl. 01) 84-87
• 94 Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood 2019; 133 (05) 415-424
• 95 Peyvandi F, Di Michele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A. Project on Consensus Definitions in Rare Bleeding Disorders of the Factor VIII/Factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost 2012; 10 (09) 1938-1943
• 96 Borhany M, Shamsi T, Fatima N, Fatima H, Naz A, Patel H. Rare bleeding disorders are not so rare in Pakistan. J Hematol Thromboembol Dis 2013; 8 (07) 124-186
• 97 Factor I deficiency (Fibrinogen deficiency). Canad Hemophil Soc 2018
• 98 Tavasoli B, Safa M, Dorgalaleh A. et al. Molecular and clinical profile of congenital fibrinogen disorders in Iran, identification of two novel mutations. Int J Lab Hematol 2020; 42 (05) 619-627
• 99 Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost 2016; 42 (04) 356-365
• 100 Lebowa W, Kenig J, Zdziarska J. Congenital dysfibrinogenemia as a rare cause of recurrent gastrointestinal bleeding. Pol Przegl Chir 2020; 92 (05) 1-5
• 101 Wypasek E, Klukowska A, Zdziarska J. et al. Genetic and clinical characterization of congenital fibrinogen disorders in Polish patients: identification of three novel fibrinogen gamma chain mutations. Thromb Res 2019; 182: 133-140
• 102 Shapiro SE, Phillips E, Manning RA. et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol 2013; 160 (02) 220-227
• 103 Zhou J, Ding Q, Chen Y. et al. Clinical features and molecular basis of 102 Chinese patients with congenital dysfibrinogenemia. Blood Cells Mol Dis 2015; 55 (04) 308-315
• 104 Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost 2015; 13 (06) 909-919
• 105 Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4 (07) 1634-1637
• 106 Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost 1999; 82 (04) 1207-1214
• 107 Girolami A, Scandellari R, Scapin M, Vettore S. Congenital bleeding disorders of the vitamin K-dependent clotting factors. Vitam Horm 2008; 78: 281-374
• 108 Dall'Osso C, Guella I, Duga S. et al. Molecular characterization of three novel splicing mutations causing factor V deficiency and analysis of the F5 gene splicing pattern. Haematologica 2008; 93 (10) 1505-1513
• 109 Petros S, Fischer J, Mössner J, Schiefke I, Teich N. Treatment of massive cecal bleeding in a 28-Year-old patient with homozygous factor V deficiency with activated factor VII. Z Gastroenterol 2008; 46 (03) 271-273
• 110 Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 1998; 103 (04) 1067-1069
• 111 Mansouritorghabeh H, Manavifar L, Mobalegh A, Shirdel A. Haemorrhagic manifestations and prevalence of factor V deficiency in north-eastern Iran. Haemophilia 2010; 16 (02) 376-380
• 112 Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009; 35 (04) 400-406
• 113 Herrmann FH, Wulff K, Auerswald G. et al; Greifswald Factor FVII Deficiency Study Group. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia 2009; 15 (01) 267-280
• 114 Napolitano M, Giansily-Blaizot M, Dolce A. et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica 2013; 98 (04) 538-544
• 115 Mariani G, Herrmann FH, Dolce A. et al; International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93 (03) 481-487
• 116 Peyvandi F, Mannucci PM, Lak M. et al. Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Haematol 1998; 102 (02) 626-628
• 117 Herrmann FH, Auerswald G, Ruiz-Saez A. et al; Greifswald Factor X Deficiency Study Group. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia 2006; 12 (05) 479-489
• 118 Santoro C, Di Mauro R, Baldacci E. et al. Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. Haemophilia 2015; 21 (04) 496-501
• 119 Ivaskevicius V, Seitz R, Kohler HP. et al; Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97 (06) 914-921
• 120 Dorgalaleh A, Naderi M, Hosseini MS. et al. Factor XIII deficiency in Iran: a comprehensive review of the literature. Semin Thromb Hemost 2015; 41 (03) 323-329
• 121 Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev 2016; 30 (06) 461-475
• 122 Mansouritorgabeh H, Rezaieyazdi Z, Pourfathollah AA, Rezai J, Esamaili H. Haemorrhagic symptoms in patients with combined factors V and VIII deficiency in north-eastern Iran. Haemophilia 2004; 10 (03) 271-275
• 123 Peyvandi F, Tuddenham EG, Akhtari AM, Lak M, Mannucci PM. Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. Br J Haematol 1998; 100 (04) 773-776
• 124 Seligsohn U, Zivelin A, Zwang E. Combined factor V and factor VIII deficiency among non-Ashkenazi Jews. N Engl J Med 1982; 307 (19) 1191-1195
• 125 Shearer MJ. Vitamin K deficiency bleeding (VKDB) in early infancy. Blood Rev 2009; 23 (02) 49-59
• 126 Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104 (05) 1243-1252
• 127 Lissitchkov T, Madan B, Djambas Khayat C. et al. Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. J Thromb Haemost 2020; 18 (04) 815-824
• 128 Lobel JS, Majumdar S, Kovats-Bell S. Successful prophylactic treatment for bleeding in a girl with severe hereditary prothrombin deficiency using a prothrombin complex concentrate (Bebulin VH). J Pediatr Hematol Oncol 2004; 26 (08) 480-483
• 129 Hennewig U, Eisert S, Wulff K, Herrmann FH, Schneider DT, Göbel U. Long-term FVII substitution in a preterm infant with severe gastrointestinal bleeding and FVII deficiency due to a homozygous donor splice mutation IVS4+1G–>A. Pediatr Hematol Oncol 2006; 23 (02) 129-133
• 130 Dorgalaleh A, Baghaipour MR, Tabibian S. et al. Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-a common clinical feature between a rare disorder and a new, common infection. Int J Lab Hematol 2020; 42 (06) e277-e279
• 131 de Jager T, Pericleous L, Kokot-Kierepa M, Naderi M, Karimi M. The burden and management of FXIII deficiency. Haemophilia 2014; 20 (06) 733-740
• 132 Gresele P, Falcinelli E, Bury L. Laboratory diagnosis of clinically relevant platelet function disorders. Int J Lab Hematol 2018; 40 (Suppl. 01) 34-45
• 133 Dorgalaleh A, Tabibian S, Shamsizadeh M. Inherited platelet function disorders (IPFDs). Clin Lab 2017; 63 (01) 1-13
• 134 Israels SJ, Kahr WH, Blanchette VS, Luban NL, Rivard GE, Rand ML. Platelet disorders in children: a diagnostic approach. Pediatr Blood Cancer 2011; 56 (06) 975-983
• 135 Lee A, Poon MC. Inherited platelet functional disorders: general principles and practical aspects of management. Transfus Apheresis Sci 2018; 57 (04) 494-501
• 136 Gresele P, Harrison P, Bury L. et al. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. J Thromb Haemost 2014; 12 (09) 1562-1569
• 137 Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006; 1 (06) 10-18
• 138 Fiore M, Nurden AT, Nurden P, Seligsohn U. Clinical utility gene card for: Glanzmann thrombasthenia. Eur J Hum Genet 2012; 20 (10) 141-157
• 139 Ezenwosu OU, Chukwu BF, Uwaezuoke NA, Ezenwosu IL, Ikefuna AN, Emodi IJ. Glanzmann's thrombasthenia: a rare bleeding disorder in a Nigerian girl. Afr Health Sci 2020; 20 (02) 753-757
• 140 Botero JP, Lee K, Branchford BR. et al; ClinGen Platelet Disorder Variant Curation Expert Panel. Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica 2020; 105 (04) 888-894
• 141 Kannan M, Ahmed RP, Jain P, Kumar R, Choudhry VP, Saxena R. Type I Glanzmann thrombasthenia: most common subtypes in North Indians. Am J Hematol 2003; 74 (02) 139-141
• 142 Platton S, McCormick Á, Bukht M, Gurney D, Holding I, Moore GW. A multicenter study to evaluate automated platelet aggregometry on Sysmex CS-series coagulation analyzers-preliminary findings. Res Pract Thromb Haemost 2018; 2 (04) 778-789
• 143 Swathi J, Gowrishankar A, Jayakumar SA, Jain K. A rare case of bleeding disorder: Glanzmann's thrombasthenia. Ann Afr Med 2017; 16 (04) 196-198
• 144 Calabrese C, Di Febo G, Areni A. et al. Severe and relapsing upper gastrointestinal bleeding in a patient with Glanzmann's thrombasthenia. Dig Dis Sci 2000; 45 (03) 633-636
• 145 Qiao Z, Chen Y, Shi W, Yang J, Song Y, Shen J. Glanzmann's thrombasthenia with spontaneous upper gastrointestinal bleeding: a case report. J Int Med Res 2020; 48 (03) 300060520904849
• 146 Poon MC. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia. Vasc Health Risk Manag 2007; 3 (05) 655-664
• 147 Poon MC, Di Minno G, d'Oiron R, Zotz R. New insights into the treatment of Glanzmann thrombasthenia. Transfus Med Rev 2016; 30 (02) 92-99
• 148 Pham A, Wang J. Bernard-Soulier syndrome: an inherited platelet disorder. Arch Pathol Lab Med 2007; 131 (12) 1834-1836
• 149 Clemetson KJ, Clemetson JM. Platelet GPIb-V-IX complex. Structure, function, physiology, and pathology. Semin Thromb Hemost 1995; 21 (02) 130-136
• 150 Bryckaert M, Rosa JP, Denis CV, Lenting PJ. Of von Willebrand factor and platelets. Cell Mol Life Sci 2015; 72 (02) 307-326
• 151 Chen Y, Ruggeri ZM, Du X. 14-3-3 proteins in platelet biology and glycoprotein Ib-IX signaling. Blood 2018; 131 (22) 2436-2448
• 152 Lanza F. Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy). Orphanet J Rare Dis 2006; 1: 46
• 153 Aliotta A, Bertaggia Calderara D, Zermatten MG, Marchetti M, Alberio L. Thrombocytopathies: not just aggregation defects-the clinical relevance of procoagulant platelets. J Clin Med 2021; 10 (05) 894
• 154 Jenkins CS, Phillips DR, Clemetson KJ, Meyer D, Larrieu MJ, Lüscher EF. Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease. J Clin Invest 1976; 57 (01) 112-124
• 155 Kirchmaier CM, Pillitteri D. Diagnosis and management of inherited platelet disorders. Transfus Med Hemother 2010; 37 (05) 237-246
• 156 Ozelo MC, Svirin P, Larina L. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol 2005; 84 (12) 816-822
• 157 Grainger JD, Thachil J, Will AM. How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults. Br J Haematol 2018; 182 (05) 621-632
• 158 Rand ML, Reddy EC, Israels SJ. Laboratory diagnosis of inherited platelet function disorders. Transfus Apheresis Sci 2018; 57 (04) 485-493
• 159 Jung N, Shim YJ. Current knowledge on inherited platelet function disorders. Cli Ped Hemato Onco 2020; 27 (01) 1-13
• 160 Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: the French experience. Haemophilia 1998; 4 (Suppl. 03) 48-52
• 161 Mousavi SH, Tabibian S, Motlagh H, Dorgalaleh A. Hemophilia A in Afghanistan, the first report. Blood Coagul Fibrinolysis 2019; 30 (07) 357-360
• 162 Mumford AD, Ackroyd S, Alikhan R. et al; BCSH Committee. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (03) 304-326
• 163 Franchini M, Lippi G. NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia. Expert Rev Hematol 2014; 7 (06) 733-740
• 164 Özdemir ZC, Düzenli Kar Y, Ceylaner S, Bör Ö. A novel mutation in the GP1BA gene in Bernard-Soulier syndrome. Blood Coagul Fibrinolysis 2020; 31 (01) 83-86
• 165 Toogeh G, Keyhani M, Sharifian R, Safaee R, Emami A, Dalili H. A study of Bernard-Soulier syndrome in Tehran, Iran. Arch Iran Med 2010; 13 (06) 549-551
• 166 Shiraishi M, Ogawa H, Ikeda M, Kawashima S, Ito K. Platelet dysfunction in Chediak-Higashi syndrome-affected cattle. J Vet Med Sci 2002; 64 (09) 751-760